Review
High-Risk Cutaneous Squamous Cell Carcinoma
Carcinoma epidermoide cutáneo de alto riesgo
Leído
27525
Vecesse ha leído el artículo
4028
Total PDF
23497
Total HTML
Compartir estadísticas
array:24 [ "pii" => "S1578219012002156" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.08.004" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "518" "copyright" => "Elsevier España, S.L. and AEDV" "copyrightAnyo" => "2011" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2012;103:567-78" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10615 "formatos" => array:3 [ "EPUB" => 46 "HTML" => 8802 "PDF" => 1767 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731011005114" "issn" => "00017310" "doi" => "10.1016/j.ad.2011.09.005" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "518" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2012;103:567-78" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 65151 "formatos" => array:3 [ "EPUB" => 3 "HTML" => 53816 "PDF" => 11332 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Carcinoma epidermoide cutáneo de alto riesgo" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "567" "paginaFinal" => "578" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "High-Risk Cutaneous Squamous Cell Carcinoma" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0040" "etiqueta" => "Figura 8" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr8.jpeg" "Alto" => 1267 "Ancho" => 1583 "Tamanyo" => 711819 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Hematoxilina eosina 20×. CEC en el que microscópicamente se aprecian varios factores de alto riesgo como son una moderada-pobre diferenciación histológica, una invasión en profundidad o Clark IV e invasión perineural de una vaina nerviosa por el CEC.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Nuño-González, F.J. Vicente-Martín, F. Pinedo-Moraleda, J.L. López-Estebaranz" "autores" => array:4 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Nuño-González" ] 1 => array:2 [ "nombre" => "F.J." "apellidos" => "Vicente-Martín" ] 2 => array:2 [ "nombre" => "F." "apellidos" => "Pinedo-Moraleda" ] 3 => array:2 [ "nombre" => "J.L." "apellidos" => "López-Estebaranz" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219012002156" "doi" => "10.1016/j.adengl.2012.08.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002156?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731011005114?idApp=UINPBA000044" "url" => "/00017310/0000010300000007/v1_201304241417/S0001731011005114/v1_201304241417/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219012002168" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.08.005" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "521" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2012;103:579-90" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4080 "formatos" => array:3 [ "EPUB" => 49 "HTML" => 3299 "PDF" => 732 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "New Therapeutic Targets in Melanoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "579" "paginaFinal" => "590" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nuevas dianas terapéuticas en el melanoma" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3060 "Ancho" => 3351 "Tamanyo" => 467780 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Simplified diagram of the some of the main intracellular pathways implicated in enhancing melanoma cell proliferation (stimulation of the cell cycle) and survival (stimulation of antiapoptic mechanisms and suppression of the proapoptotic mechanisms). Many melanomas have constitutive activation of growth factor receptors with tyrosine-kinase activity (TKR) (for example, c-kit, PDGFR-α, and/or EGFR), whether through amplifications or mutations of the genes that encode them. Likewise, they show activation of the signaling pathways of the mitogen-activated protein (MAP) kinases (RAS/RAF/MEK/ERK), due essentially to <span class="elsevierStyleItalic">NRAS</span> and <span class="elsevierStyleItalic">BRAF</span> mutations. Often the phosphatidyl-inositol 3 kinase (PI3K) (PI3K/AKT) pathway is also activated indirectly as a result of <span class="elsevierStyleItalic">NRAS</span> mutations and <span class="elsevierStyleItalic">AKT</span> amplification, and is especially favored by the loss of the inhibitory role of PTEN, resulting from mutations, deletions, or silencing of the tumor suppressor gene <span class="elsevierStyleItalic">PTEN</span>. In addition, deletions, silencing, and mutations of <span class="elsevierStyleItalic">CDKN2A</span> are implicated in activation of the cell cycle. These genetic aberrations lead to defects in the 2 proteins encoded by this gene (p16 and p14), as well as in CDK4 and CCND1 (cyclin D1) amplifications. This all has a deleterious impact on the activity of the proapoptotic protein p53 (which may also be mutated in some cases) and overexpression of antiapoptotic proteins of the Bcl-2 family.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R.M. Martí, A. Sorolla, A. Yeramian" "autores" => array:3 [ 0 => array:2 [ "nombre" => "R.M." "apellidos" => "Martí" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Sorolla" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Yeramian" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101100514X" "doi" => "10.1016/j.ad.2011.08.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101100514X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002168?idApp=UINPBA000044" "url" => "/15782190/0000010300000007/v1_201304241318/S1578219012002168/v1_201304241318/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219012002120" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.08.001" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "533" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2012;103:561-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2340 "formatos" => array:3 [ "EPUB" => 44 "HTML" => 1750 "PDF" => 546 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Opinion Articles</span>" "titulo" => "New Information Concerning the History of the Olavide Museum and Its Wax Models" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "561" "paginaFinal" => "566" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nuevas aportaciones a la historia del Museo Olavide y sus figuras" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 896 "Ancho" => 1949 "Tamanyo" => 275614 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Enrique Zofío Dávila's military service record.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Conde-Salazar Gomez, F. Heras-Mendaza" "autores" => array:2 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Conde-Salazar Gomez" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Heras-Mendaza" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731011005266" "doi" => "10.1016/j.ad.2011.11.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731011005266?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002120?idApp=UINPBA000044" "url" => "/15782190/0000010300000007/v1_201304241318/S1578219012002120/v1_201304241318/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "High-Risk Cutaneous Squamous Cell Carcinoma" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "567" "paginaFinal" => "578" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "A. Nuño-González, F.J. Vicente-Martín, F. Pinedo-Moraleda, J.L. López-Estebaranz" "autores" => array:4 [ 0 => array:4 [ "nombre" => "A." "apellidos" => "Nuño-González" "email" => array:1 [ 0 => "almudenanuno@hotmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "F.J." "apellidos" => "Vicente-Martín" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "F." "apellidos" => "Pinedo-Moraleda" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "J.L." "apellidos" => "López-Estebaranz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Unidad de Dermatología, Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unidad de Anatomía Patológica, Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Carcinoma epidermoide cutáneo de alto riesgo" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 760 "Ancho" => 951 "Tamanyo" => 436026 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Cutaneous squamous cell carcinoma around a nerve sheath. Perineural invasion is clearly visible (hematoxylin-eosin, original magnification ×100).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, after basal cell carcinoma (BCC). The incidence of cSCC has increased considerably over the past 20 years, and epidemiological studies predict that it will increase even further in the coming decade.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–4</span></a> In Spain, the annual incidence of cSCC per 100 000 population is estimated at 72 for women and 100.8 for men.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Most cases of cSCC are localized and can be treated by surgical excision or other local procedures.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,6,7</span></a> One subset of the disease, however, is more biologically aggressive and has a greater tendency toward local recurrence, lymphatic spread, and, occasionally, invasion of distant organs. The percentage of primary cSCCs that metastasize varies between case series but is usually under 5%. In high-risk cSCC, this percentage is higher,<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> ranging from 15%<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> to 38%,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> depending on the study. Given the increasing incidence of cSCC and the poor prognosis of a subset of patients, physicians need to be aware of the features that increase the risk of local recurrence and metastases in this type of cancer.</p><p id="par0010" class="elsevierStylePara elsevierViewall">High-risk cSCC has been defined as cSCC with a risk of recurrence, lymph node metastasis, and/or distant metastasis greater than 5%, determined on the basis of tumor characteristics and patient factors.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> The American Joint Committee on Cancer (AJCC) recently published the seventh edition of its Cancer Staging Manual, which contains new TNM staging criteria for nonmelanoma skin carcinomas.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,10</span></a> The criteria included in previous editions of the AJCC manual were not appropriate for staging patients with cSCC. The new staging scheme not only considers tumor size (>2<span class="elsevierStyleHsp" style=""></span>cm), but also other important factors, such as thickness (>2<span class="elsevierStyleHsp" style=""></span>mm), Clark level (≥ IV), location (ear, lip), and differentiation (poorly differentiated or undifferentiated).<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,10</span></a> If a tumor has 2 or more high-risk features, its T classification is upstaged by 1 level, a change that implies a worse prognosis (<a class="elsevierStyleCrossRefs" href="#tbl0005">Tables 1 and 2</a>). Another significant change in this edition of the manual is the fact that cSCC is now staged separately from other nonmelanoma skin carcinomas because it behaves differently from BCC and Merkel cell carcinoma; these separate staging criteria for cSCC were introduced to improve prognostic estimates and approaches to treatment. The new criteria also exclude certain specific sites, such as the eyelid, penis, and vulva. The authors make the point that the majority of cSCC tumors occur on the head and neck.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> cSCC of the eyelid is now staged as an ophthalmic tumor, and penile and vulvar SCC are excluded from the cSCC staging criteria because of their close association with human papillomavirus (HPV) and distinct biological behavior.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> The TNM classification established in the seventh edition of the AJCC manual provides a more accurate prognosis for cSCC; it should be noted, however, that other high-risk features not included in this classification are also associated with higher rates of recurrence and metastasis. Our aim in this article is to review the features of high-risk cSCC and the degree to which they influence prognosis and therapeutic management.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Prognostic Factors for High-Risk cSCC</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Tumor Size</span><p id="par0015" class="elsevierStylePara elsevierViewall">Larger size, in terms of maximum horizontal diameter, has traditionally been correlated with higher rates of local recurrence and regional metastasis and lower rates of survival. In fact, until the latest edition of the AJCC manual was published, tumor size was the sole criterion used to establish a T classification (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The importance of tumor size has been confirmed by both univariate and multivariate analyses.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> Several studies have established 2<span class="elsevierStyleHsp" style=""></span>cm as the breakpoint after which tumors are more likely to metastasize; tumors larger than 2<span class="elsevierStyleHsp" style=""></span>cm across are twice as likely to recur and 3 times as likely to metastasize as smaller tumors.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,6,10–13</span></a> However, physicians should be aware that tumors smaller than 2<span class="elsevierStyleHsp" style=""></span>cm can also metastasize, as observed in a prospective study of 266 patients with metastatic cSCC of the head and neck in which the majority of patients had tumors with a maximum diameter of less than 2<span class="elsevierStyleHsp" style=""></span>cm.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> It is therefore necessary to take other factors into account when determining the risk of metastasis in cSCC.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Thickness and Depth</span><p id="par0020" class="elsevierStylePara elsevierViewall">Tumor thickness is defined as the maximum depth of invasion by the tumor, measured in millimeters; it is equivalent to the Breslow depth in melanoma<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The method used to measure the thickness of a cSCC is an important consideration. cSCCs are not easy to measure because they often present as crater-shaped lesions or have a central ulcer. Moreover, measurement criteria vary from 1 pathologist to another. In a 2008 study of 615 patients with cSCC, Branscht et al.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> assessed several variables, including tumor thickness and risk of metastasis, and concluded that cSCCs with a thickness of less than 2<span class="elsevierStyleHsp" style=""></span>mm were associated with practically no risk of recurrence or metastasis. However, the risk of metastasis rose to 4% for tumors 2.1 to 6.0<span class="elsevierStyleHsp" style=""></span>mm thick and to 16% for tumors more than 6<span class="elsevierStyleHsp" style=""></span>mm thick. Veness et al.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> observed no metastases in cSCCs less than 2<span class="elsevierStyleHsp" style=""></span>mm thick. Metastasis did occur, however, in 17% of tumors 2 to 4<span class="elsevierStyleHsp" style=""></span>mm thick and in 83% of tumors more than 4<span class="elsevierStyleHsp" style=""></span>mm thick.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">The anatomic depth of invasion, expressed as a Clark level, is an important consideration at sites where the dermis and cell tissue are thinner. For example, a cSCC on the ear is more aggressive than a tumor of the same thickness on the back. Clayman et al.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> observed that cSCCs with a Clark level of IV or higher were associated with a worse prognosis (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">Tumor thickness and depth of invasion are important prognostic factors in cSCC, and both are used to define high-risk features in the latest edition of the AJCC manual (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). The most recent AJCC staging criteria classify invasion of the maxilla, mandible, orbit, or temporal bone as T3 and skull-base invasion as T4 (the latter is associated with a worse prognosis because it implies perineural and bone invasion).<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Perineural Invasion</span><p id="par0035" class="elsevierStylePara elsevierViewall">Perineural invasion occurs when tumor cells surround and enter a nerve sheath and spread in either direction along the nerve, either towards the surface of the skin or into the deeper tissues<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16,17</span></a> (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>). This type of spread occurs in 5% to 10% of cases of cSCC. Perineural invasion can be detected clinically and histopathologically and is associated with higher rates of recurrence and lymph node invasion<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> as well as lower survival rates<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> (<a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>). Clinical symptoms of perineural invasion include paresis, paresthesia, pain, and dysesthesia, and histologic evidence of the process can be obtained from a tissue sample following excision. Whether evidenced by clinical or histological manifestations, perineural invasion is always associated with a poorer clinical course owing to the uneven spread of the tumor along the nerves. Perineural invasion in cSCC is associated with poor tumor differentiation, larger size, and higher rates of recurrence. Perineural invasion has consistently been identified as an indicator of poor prognosis<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a>: cSCCs with perineural invasion carry a significantly higher risk of local recurrence, distant metastasis, and disease-specific death than those without such invasion.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> Ross et al.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> recently demonstrated that perineural invasion affecting nerves greater than 0.1<span class="elsevierStyleHsp" style=""></span>mm in diameter is associated with metastasis; they do not consider perineural invasion affecting nerves less than 0.1<span class="elsevierStyleHsp" style=""></span>mm in diameter to be a risk factor, although additional studies are needed to confirm this hypothesis.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Lymphatic or Vascular Vessel Invasion</span><p id="par0040" class="elsevierStylePara elsevierViewall">Cases of cSCC with lymphatic or vascular vessel invasion have greater risk of regional metastasis. One study found lymphovascular invasion in 40% of patients with lymph node metastases and, by contrast, in 8% of patients without metastatic disease; a multivariate analysis in the same study showed that lymphovascular invasion was a predictor of metastasis.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> Vascular invasion causes cancer to spread via the bloodstream. The most common sites of metastasis are the lungs, liver, bone, brain, and skin.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Unlike perineural invasion, however, lymphatic and vascular invasion are not considered in most studies, and therefore they are not included in the most recent AJCC staging criteria.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Histologic Subtype</span><p id="par0045" class="elsevierStylePara elsevierViewall">There are several histologic subtypes of cSCC, and they do not all exhibit the same behavior. Cassarino et al.<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21,22</span></a> reviewed the histologic subtypes and classified them by metastatic rate. The most aggressive subtypes are desmoplastic carcinoma, adenosquamous carcinoma, and invasive Bowen disease as well as de novo cSCC, defined as a tumor arising not in a precursor lesion such as an actinic keratosis but in a scar or an area of chronic inflammation.<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22,23</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">In a subsequent review, Yanofsky et al.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> also identified de novo cSCC and desmoplastic carcinoma as high-risk cSCC variants. The same review also mentioned clear-cell cSCC. Because clear-cell cSCC is very rare, it is difficult to statistically determine its metastatic potential; the authors noted, however, that perineural and perivascular invasion tend to be present in this variant. The review also identified cSCC with single-cell infiltrates as a more aggressive tumor subtype. Other subtypes, in particular cSCC arising in actinic keratosis (the most common variant, accounting for 97% of cases), are more benign. Of these tumors, the most aggressive are those which originate in hypertrophic or proliferative actinic keratoses.<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22,23</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">It is also essential to determine the degree of differentiation of a cSCC tumor whatever its histologic subtype. In Broders's index, cSCC tumors are classified by the percentage of differentiated cells: grade I, more than 75%; grade II, 50% to 75%; grade III, 25% to 50%; and grade IV, less than 25%.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> It is common practice to classify cSCCs as well-differentiated, moderately differentiated, or poorly differentiated. Logically, poorly differentiated tumors are the most aggressive.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,6,10,22</span></a> The AJCC considers a cSCC tumor to be high grade if it presents poor differentiation, necrosis, deep invasion, high mitotic activity, and spindle cell characteristics. Several studies have shown that poorly differentiated cSCCs have a greater tendency to metastasize<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,13</span></a> (<a class="elsevierStyleCrossRef" href="#fig0025">Fig. 5</a>). Therefore, tumors must be properly classified histologically in order to determine the associated risk.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> Poor differentiation is included as a predictor of poor prognosis in the staging criteria of the seventh edition of the AJCC manual.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Immunosuppression</span><p id="par0060" class="elsevierStylePara elsevierViewall">In immunosuppressed patients, especially recipients of solid-organ (i.e. kidney or heart) transplants, cSCC occurs more frequently and progresses more aggressively than in the general population.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,17</span></a> Despite the fact that immunosuppression is not included in the latest AJCC staging criteria, Farasat et al.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> recommend taking it into account by adding an “I” to the staging designation. In the general population, cases of BCC outnumber cases of cSCC by 4 to 1; among recipients of solid-organ transplants, however, cSCC is more common,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> outnumbering cases of BCC by a factor of anywhere from 1.8 to 15, depending on the case series.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,17</span></a> One study has shown that patients with both SCC and BCC are less likely to develop further BCCs after initial presentation; this may explain the lower prevalence of BCC among immunosuppressed patients. It should be noted, however, that this study compared patients who had SCC and BCC with patients who only had BCC and did not take immunosuppression into account.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">The likelihood of a patient developing cSCC also depends on the type of transplant he or she has received. cSCC is more likely to occur in heart transplant recipients than in kidney transplant recipients, and less likely to occur in liver transplant recipients than in either of the other 2 groups.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> This difference appears to be related to the degree of immunosuppression used in each type of patient: heart transplant recipients tend to be the most immunosuppressed, followed by kidney transplant recipients and, finally, liver transplant recipients.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,12</span></a> Greater immunosuppression may facilitate greater tumor progression. It has recently been postulated, however, that HPV may have an oncogenic role in the development of cSCC in immunosuppressed patients.<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">26,27</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">In immunosuppressed patients, cSCC is not only more prevalent but also more aggressive and more likely to metastasize. Metastatic rates of approximately 12.9% have been reported in this group of patients.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">The immune deficiency associated with HIV infection is not associated with the development of high-risk cSCCs, except in the case of perianal cSCC, in which HPV plays a crucial oncogenic role. Patients with chronic lymphocytic leukemia tend to develop unusually aggressive and recurrent cSCCs with high-risk features, such as a horizontal diameter of more than 2<span class="elsevierStyleHsp" style=""></span>cm, perineural invasion, and poor differentiation.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">HPV Infection</span><p id="par0080" class="elsevierStylePara elsevierViewall">HPV has a clear causal relationship with mucosal SCC, but no such relationship between HPV and cSCC has been clearly demonstrated. There are various types of HPV. Alpha-HPV infects mucosal sites and is associated with cervical carcinoma and other forms of cancer. Beta-HPV is associated with cSCC.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,29</span></a> Studies have shown that more HPV genotypes are found in immunocompromised patients than in immunocompetent patients, although the incidence of HPV infection is also high among the latter. It is estimated that 90% of cSCC tumors in immunocompromised patients contain beta-HPV, compared with 50% in immunocompetent patients.<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">26,29</span></a> Infection by a greater number of HPV serotypes has been observed in elderly patients, probably because of immunosenescence, the relative immune deficiency brought on by the aging process.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> Different case series have variously identified HPV 23, HPV 8, and HPV 5 as the most common serotype in cSCC patients,<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a> although other serotypes have also been associated with the disease.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> Serotypes vary by geographic area.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a> The relationship between HPV and more aggressive cSCC has not been proven. Mutations in the <span class="elsevierStyleItalic">EVER1</span> and <span class="elsevierStyleItalic">EVER2</span> genes are associated with a higher risk of HPV and a greater likelihood of developing cSCC.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">High-Risk Sites and Drainage Regions</span><p id="par0085" class="elsevierStylePara elsevierViewall">The seventh edition of the AJCC manual specifies 2 high-risk anatomic locations: the ear and the lip.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> Overall, 2% to 6% of cSCCs metastasize, but cSCCs located on the ear and lip have a metastatic rate of 14% to 16%.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">32</span></a> Tumors at these high-risk sites are therefore upstaged.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> This higher metastatic rate has traditionally been attributed to the fact that the ear and lip are highly innervated and vascularized and have little subcutaneous tissue. These attributes facilitate the invasion of deep structures and rapid spread (<a class="elsevierStyleCrossRef" href="#fig0030">Fig. 6</a>). In 1 prospective study, however, Brantsch et al.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> observed no difference in the rates of metastasis and recurrence for cSCC tumors of the lip as compared with tumors at other sites; they did, however, find higher metastasis and recurrence rates for cSCCs of the ear. Other authors have identified the scalp as a high-risk location, especially in patients with male pattern baldness, a condition that exposes the scalp to chronic actinic damage.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> cSCC tumors that arise from chronic inflammatory processes—called de novo cSCCs by some authors—are more aggressive.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> De novo cSCCs have been reported to arise from a multitude of chronic processes: burn scars, chronic ulcers, lupus erythematosus, fistulas secondary to chronic osteomyelitis, leprosy, hidradenitis suppurativa, granuloma inguinale, erythema ab igne, congenital poikiloderma, dystrophic epidermolysis bullosa, porokeratosis of Mibelli, necrobiosis lipoidica, lichen sclerosus et atrophicus, lupus vulgaris, and even epidermal cysts.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23,34</span></a> De novo cSCC has a metastatic rate as high as 38% according to some authors and is often diagnosed late.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> cSCC tumors in areas that drain to the parotid lymph nodes are associated with a worse prognosis; the most frequent site for such tumors is the cheek, followed by the ear, temple, forehead, and scalp<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> (<a class="elsevierStyleCrossRef" href="#fig0035">Fig. 7</a>). Studies have shown that metastasis to the parotid nodes is associated with poorer disease control and that metastasis to cervical nodes worsens prognosis to a greater extent than isolated parotid lymph node enlargement; a staging system that differentiates between parotid and neck disease has therefore been proposed.<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32,36</span></a> Parotid metastases are predictors of poor outcomes, but the prognosis is worse if the cervical nodes are also involved. In routine practice this staging system has not been adopted and it was not included in the latest AJCC guidelines.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><elsevierMultimedia ident="fig0030"></elsevierMultimedia><elsevierMultimedia ident="fig0035"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Inadequate Tumor Resection or Tumor with Tendency Towards Recurrence</span><p id="par0090" class="elsevierStylePara elsevierViewall">cSCCs that have been inadequately excised (with very narrow or histologically positive surgical margins) and those that recur despite histologic confirmation of tumor-free margins, are associated with poorer disease control.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,4,17</span></a> Up to 50% of tumors with positive margins recur<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> and therefore may also metastasize. Although no predefined excision margins have been established for cSCC, this type of tumor requires margins of at least 2 to 4<span class="elsevierStyleHsp" style=""></span>mm (or greater for deeper tumors).<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> In a study of patients with metastatic cSCC, Oddonne et al.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> reported that 57% of patients with lymph node metastases had positive or very narrow (less than 2<span class="elsevierStyleHsp" style=""></span>mm) excision margins. In another study, 51% of patients who developed lymph node metastases had a recurrent primary lesion.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> A tumor excised inadequately, with positive or very narrow margins, should therefore be considered to have a high risk of recurrence.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Expression of Tumor Genes and Genetic Markers</span><p id="par0095" class="elsevierStylePara elsevierViewall">Various histologic and genetic markers are associated with more aggressive cSCCs. The epidermal growth factor receptor (EGFR) is associated with poor prognosis, and tumors that express it are more aggressive.<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">35,37</span></a> EGFR is a possible therapeutic target, as inhibition of this pathway has been shown to increase survival. Other proteins, when expressed in cSCC tumors, are also associated with a poor prognosis. STAT3 has been associated with poor differentiation, E-cadherin with lymph node metastasis, and CD44 with recurrent cSCC; in addition, Ets-1 appears to be involved in the pathogenesis of invasive cSCC.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Management of High-Risk cSCC</span><p id="par0100" class="elsevierStylePara elsevierViewall">The first step in the treatment of high-risk cSCC is to identify the tumor as such according to the features summarized in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>. The lack of a prognostic model for cSCC capable of safely and reliably determining an individual's risk of metastasis and death complicates therapeutic decisions and justifies the lack of uniformity in cSCC treatment.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0105" class="elsevierStylePara elsevierViewall">The number of features required to identify a cSCC as high-risk is the subject of some debate. Most authors consider that the presence of just 1 high-risk feature is sufficient to classify a tumor as high-risk, while some authors argue that 2 or more features must be present.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> In any event, most patients with high-risk cSCC exhibit multiple high-risk features (<a class="elsevierStyleCrossRef" href="#fig0040">Fig. 8</a>).</p><elsevierMultimedia ident="fig0040"></elsevierMultimedia><p id="par0110" class="elsevierStylePara elsevierViewall">Most metastases of cSCC occur within 2 years of the initial diagnosis,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> although there have been reports of late metastasis (5 to 10 years after diagnosis).<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,12</span></a> Regional lymphatic metastases are not normally detected at the same time as the primary tumor; they are usually found after the primary tumor has been treated.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> In cSCC, 80% of metastases involve locoregional lymph nodes. Distant metastases to solid organs usually affect the lungs, liver, brain, skin, and bones.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">Because cSCCs occur most frequently on the head and neck, regional metastases usually develop in the parotid and/or cervical lymph nodes.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,32</span></a> For cSCCs at other sites, affected nodes will depend on the precise location of the tumor. cSCCs on the arms and legs will affect axillary and inguinal lymph nodes, respectively; tumors on the trunk can affect various lymph nodes.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The first-line treatment for high-risk cSCC is Mohs micrographic surgery<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> or conventional surgery with margins wide enough to ensure the removal of any malignant infiltration. After surgery, the patient must be followed up regularly to monitor for local and distant recurrences. Patients with high-risk cSCC should undergo routine imaging studies and clinical check-ups every 4 to 6 months. There has been insufficient research to form a consensus on the need for adjuvant radiation therapy, sentinel node biopsy, or prophylactic lymphadenectomy.<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18,39,40</span></a></p><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Tumor Staging</span><p id="par0125" class="elsevierStylePara elsevierViewall">Before any treatment is initiated, a rigorous examination should be performed to rule out regional lymphadenopathy. If any enlarged lymph nodes are found, fine needle aspiration or excisional biopsy should be performed to ascertain whether they are metastatic.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p><p id="par0130" class="elsevierStylePara elsevierViewall">Radiographic imaging is the standard method for determining the subclinical spread of a tumor; however, the most appropriate imaging technique and the subset of patients who require such studies have not yet been established. Ultrasound of the cervical lymph nodes is an inexpensive, highly sensitive technique recommended by various authors for monitoring cSCC, particularly high-risk cases.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11,41</span></a> This technique can also be useful for screening and monitoring patients with high-risk cSCC of the head and neck, because the lymph nodes in these areas are usually superficial.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Computed tomography is generally superior for detecting lymph node central necrosis, extracapsular spread, skull-base invasion, and cartilage involvement.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">42</span></a> Magnetic resonance imaging is better for detecting neurotrophic tumors, defining tissue planes, and distinguishing dense connective tissue from muscle.<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">43</span></a> Positron emission tomography is recommended for the detection of metastasis in areas that are necrosed, fibrosed, or affected by radiation therapy. Therefore, this technique is often used following surgery or radiation therapy to detect persistent or recurrent malignancy and to determine its severity.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Assessment of Immune Status</span><p id="par0135" class="elsevierStylePara elsevierViewall">The patient's immune status is another important factor in the management of patients with cSCC, especially solid-organ transplant recipients, who are at high risk of developing recurrent metastatic disease.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,13,15,45</span></a> Reduction of immunosuppression has been associated with a lower rate of new tumor formation and a better clinical course in aggressive cSCC.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> A reduction of immunosuppression is therefore recommended in immunosuppressed patients who develop cSCC; this should be managed in a multidisciplinary manner by the transplant or oncology team in conjunction with the dermatologist. It should be noted that monotherapy immunosuppression carries less risk than multiple-drug immunosuppression. New immunosuppressants such as sirolimus are associated with a lower incidence of cSCC as compared to calcineurin inhibitors.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">Another factor clearly related to immune status is sun exposure. Because they have fewer repair mechanisms to protect against acute and chronic actinic damage, immunosuppressed patients should always use high-protection sunscreen. Since they have a higher risk of developing skin cancer, immunosuppressed patients should also have regular dermatologic examinations because early diagnosis is the most important step in treating cutaneous tumors.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a></p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conventional Surgery and Mohs Micrographic Surgery</span><p id="par0145" class="elsevierStylePara elsevierViewall">While various approaches have been used to treat high-risk cSCC, complete surgical excision with histologically tumor-free margins remains the best option. Other alternatives, such as cryotherapy, electrocoagulation, topical treatments (imiquimod, 5-fluorouracil, topical retinoids), and photodynamic therapy,<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,46</span></a> are not recommended for high-risk cSCC.</p><p id="par0150" class="elsevierStylePara elsevierViewall">cSCCs should be appropriately excised with surgical margins of 4 to 10<span class="elsevierStyleHsp" style=""></span>mm, depending on the size of the tumor.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,11</span></a> Tumors less than 2<span class="elsevierStyleHsp" style=""></span>cm across are resolved with surgical margins of 4<span class="elsevierStyleHsp" style=""></span>mm in 95% of cases, and surgical margins of at least 6<span class="elsevierStyleHsp" style=""></span>mm are needed to achieve tumor-free margins in tumors with a diameter greater than 2 cm.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Nevertheless, Mohs micrographic surgery is the preferred treatment for these larger tumors.</p><p id="par0155" class="elsevierStylePara elsevierViewall">Mohs micrographic surgery is the first-line treatment for high-risk cSCC. Conventional surgery has a higher cure rate than Mohs surgery overall, but it is less successful with tumors that are more than 2<span class="elsevierStyleHsp" style=""></span>cm across, poorly differentiated, or recurrent. There have been no studies comparing the effectiveness of Mohs and conventional surgery in the treatment of high-risk cSCC. Mohs surgery is also indicated in cases of cSCC with perineural infiltration. Mohs surgery is not useful in cSCCs with bone invasion, involvement by contiguity of the parotid gland, in-transit metastases, or spread along major nerve branches. In such cases, a multidisciplinary approach is required to ensure complete excision of the tumor.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Sentinel Node Biopsy</span><p id="par0160" class="elsevierStylePara elsevierViewall">There is no consensus concerning the use of selective sentinel node biopsy (SNB) in patients with high-risk cSCC. SNB makes it possible to avoid unnecessary prophylactic lymphadenectomies and to detect micrometastases. Patients who undergo this procedure can benefit from early treatment, (i.e. lymphadenectomy) before nodal metastasis can be detected clinically or radiologically. SNB is known to be associated with much lower morbidity than lymphadenectomy, but there have been no prospective studies comparing SNB and prophylactic lymphadenectomy. Such studies would be necessary in order to determine whether SNB increases survival or not.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">47</span></a> Several authors have recommend the use of SNB in immunosuppressed patients and in cSCCs that are recurrent, poorly differentiated, larger than 4<span class="elsevierStyleHsp" style=""></span>cm across, or which arise in a chronic inflammatory lesion, a scar, the lip, or the ear.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">40</span></a> However, other authors recommend the use of SNB on any patient with a cSCC that exhibits a high-risk feature.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a></p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Prophylactic Lymphadenectomy</span><p id="par0165" class="elsevierStylePara elsevierViewall">Prophylactic lymphadenectomy is the removal of the ipsilateral neck lymph nodes when a tumor is at stage N0, defined either clinically or with imaging techniques. Some authors recommend performing a prophylactic lymphadenectomy when any high-risk features are present.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Veness<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> reported that up to 24% of patients with no clinical evidence of nodal involvement who underwent a prophylactic lymphadenectomy did, in fact, have local metastases. However, the decision to perform a prophylactic lymphadenectomy solely on the basis of high-risk features is controversial because prophylactic lymphadenectomy is an aggressive procedure associated with high morbidity, and because high-risk cSCC usually occurs in elderly patients with comorbidities,<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> a factor that further limits the number of cases in which the procedure is indicated.</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Radiation Therapy</span><p id="par0170" class="elsevierStylePara elsevierViewall">Radiation therapy can be used to treat high-risk cSCC, but it generally yields poorer outcomes than surgery. The use of radiation therapy is limited by the fact that the technique does not allow the confirmation of margins, an especially important concern in the case of large or thick tumors. Radiation therapy is therefore generally reserved for elderly patients with inoperable tumors. However, at some sites, such as the lower lip, radiation therapy achieves results similar to those obtained by surgical treatment and can provide better functional and cosmetic outcomes.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Adjuvant Radiation Therapy</span><p id="par0175" class="elsevierStylePara elsevierViewall">Adjuvant radiation therapy has been used in some patients with high-risk SCCs, especially in cases where perineural invasion, positive (or indeterminate) surgical margins, or in-transit metastases are present. There have been no randomized studies comparing the outcomes of surgery plus adjuvant radiation therapy to the outcomes of surgery alone.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> The benefits of adjuvant radiation therapy are therefore subject to debate, although many authors have recommended this technique.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,18,35</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">cSCCs with significant perineural invasion (i.e. affecting nerves with a diameter greater than 0.1<span class="elsevierStyleHsp" style=""></span>mm) have higher rates of recurrence, even following excision with tumor-free surgical margins. Adjuvant radiation therapy is indicated in such cases, although the utility of this approach has not been clearly established.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> In cases of cSCC with perineural invasion in which complete surgical excision is not possible, radiation therapy is used despite poor prognosis.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> Adjuvant radiation therapy has also been used to treat cSCCs with positive or indeterminate surgical margins, but the risk of local recurrence and regional or distance metastasis is higher than in cases where the margins are free of neoplastic infiltration.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Chemotherapy</span><p id="par0185" class="elsevierStylePara elsevierViewall">We now have chemotherapy drugs that have been shown to increase survival in patients with high-risk or locally advanced cSCCs. Small doses of oral retinoids reduce the number of cSCCs and recurrence in immunosuppressed patients and are therefore indicated for patients with multiple high-risk tumors.<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">45,46</span></a> Oral capecitabine or its active form, oral 5-fluorouracil, have been shown to effectively treat locally advanced cSCCs.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Good results have also been obtained by combining oral 5-fluorouracil with subcutaneous interferon alfa for 2 to 3 weeks, and by combining oral retinoids with subcutaneous interferon alfa.<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">28,46</span></a> Drugs that inhibit EGFR, a receptor expressed in aggressive cSCCs, have also shown good preliminary results.<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">46</span></a> This category of drugs includes gefitinib, which in some trials has been shown to increase survival in patients with cSCC. EGFR inhibitors are used to treat other types of cancer, such as lung and colorectal carcinomas, and have been shown to increase survival. Cetuximab, another EGFR inhibitor, has yielded positive results both alone and in combination with 5-fluorouracil and cisplatin, and has been shown to improve prognosis in patients with locally advanced cSCC, both with and without radiation therapy.<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">46,48–50</span></a></p></span></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conclusions</span><p id="par0190" class="elsevierStylePara elsevierViewall">There is no well-established definition of high-risk cSCC. Nevertheless, it is usually defined as cSCCs associated with a greater than 5% risk of recurrence, lymph node metastasis, and/or distant metastasis (risk level being determined on the basis of certain high-risk features). In the seventh and most recent edition of its Cancer Staging Manual, the AJCC updated its staging criteria to include features that are predictors of a poorer clinical course. The result is a better staging scheme that provides a more accurate prognosis for patients. However, other high-risk features also associated with poorer outcomes were not included in the revised staging criteria. The following are the features associated with high-risk cSCC: tumor size greater than 2<span class="elsevierStyleHsp" style=""></span>cm, thickness greater than 2<span class="elsevierStyleHsp" style=""></span>mm, a Clark level of IV or higher, perineural invasion, lymphatic or vascular invasion, poor differentiation, certain histologic subtypes (desmoplastic or adenosquamous carcinoma, invasive Bowen disease, or cSCCs arising in areas of chronic inflammation), immunosuppression, HPV infection, high-risk anatomic location (ear or lip), expression of certain tumor genes, and inadequate tumor resection.</p><p id="par0195" class="elsevierStylePara elsevierViewall">In the therapeutic management of high-risk cSCC, it is essential to detect any high-risk features, stage the disease properly, assess the patient's degree of immunosuppression, and treat the tumor surgically, either with conventional surgery with sufficient margins or, preferably, with Mohs surgery. In certain cases, SNB or lymphadenectomy should be considered, although there is no consensus regarding whether SNB increases survival. Various authors have recommend the use of SNB in immunosuppressed patients and patients with cSCCs that are poorly differentiated, more than 4<span class="elsevierStyleHsp" style=""></span>cm across, recurrent, or have arisen in a chronic inflammatory lesion, a scar, the lip, or the ear. However, other authors recommend the use of SNB on any patient with a cSCC that exhibits any high-risk feature. Radiation therapy or adjuvant radiation therapy may also be useful in certain cases, and chemotherapy, used in some cases of cSCC with distant metastasis, has shown good results.</p><p id="par0200" class="elsevierStylePara elsevierViewall">Therefore, it is very important to identify patients with high-risk cSCC, monitor them closely, detect recurrence and metastases early, and provide more aggressive treatment in order to reduce the morbidity and mortality associated with this disease.</p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflicts of Interest</span><p id="par0205" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:2 [ "identificador" => "xres96139" "titulo" => "Abstract" ] 1 => array:2 [ "identificador" => "xpalclavsec83298" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres96138" "titulo" => "Resumen" ] 3 => array:2 [ "identificador" => "xpalclavsec83297" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Prognostic Factors for High-Risk cSCC" "secciones" => array:10 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Tumor Size" ] 1 => array:2 [ "identificador" => "sec0120" "titulo" => "Thickness and Depth" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Perineural Invasion" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Lymphatic or Vascular Vessel Invasion" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Histologic Subtype" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "Immunosuppression" ] 6 => array:2 [ "identificador" => "sec0045" "titulo" => "HPV Infection" ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "High-Risk Sites and Drainage Regions" ] 8 => array:2 [ "identificador" => "sec0055" "titulo" => "Inadequate Tumor Resection or Tumor with Tendency Towards Recurrence" ] 9 => array:2 [ "identificador" => "sec0060" "titulo" => "Expression of Tumor Genes and Genetic Markers" ] ] ] 6 => array:3 [ "identificador" => "sec0065" "titulo" => "Management of High-Risk cSCC" "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0070" "titulo" => "Tumor Staging" ] 1 => array:2 [ "identificador" => "sec0075" "titulo" => "Assessment of Immune Status" ] 2 => array:2 [ "identificador" => "sec0080" "titulo" => "Conventional Surgery and Mohs Micrographic Surgery" ] 3 => array:2 [ "identificador" => "sec0085" "titulo" => "Sentinel Node Biopsy" ] 4 => array:2 [ "identificador" => "sec0090" "titulo" => "Prophylactic Lymphadenectomy" ] 5 => array:2 [ "identificador" => "sec0095" "titulo" => "Radiation Therapy" ] 6 => array:2 [ "identificador" => "sec0100" "titulo" => "Adjuvant Radiation Therapy" ] 7 => array:2 [ "identificador" => "sec0105" "titulo" => "Chemotherapy" ] ] ] 7 => array:2 [ "identificador" => "sec0110" "titulo" => "Conclusions" ] 8 => array:2 [ "identificador" => "sec0115" "titulo" => "Conflicts of Interest" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2011-04-25" "fechaAceptado" => "2011-09-29" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec83298" "palabras" => array:4 [ 0 => "Cutaneous squamous cell carcinoma" 1 => "High-risk factors" 2 => "Metastases" 3 => "Recurrence" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec83297" "palabras" => array:4 [ 0 => "Carcinoma epidermoide cutáneo" 1 => "Factores de alto riesgo" 2 => "Metástasis" 3 => "Recidiva" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and its incidence has increased in recent decades. Most cSCCs are successfully treated by surgery, but local and distant metastases develop in approximately 5% of cases; this proportion is higher in certain forms of cSCC with high-risk factors, namely: tumor size >2<span class="elsevierStyleHsp" style=""></span>cm, depth >2<span class="elsevierStyleHsp" style=""></span>mm, Clark level ≥IV, perineural invasion, lymphovascular invasion, poor differentiation, certain histologic subtypes (desmoplastic or adenosquamous carcinoma, invasive Bowen disease, or a cSCC arising in areas of chronic inflammation), immunosuppression, human papillomavirus infection, high-risk anatomic location (pinna of the ear, labial mucosa), expression of certain tumor genes, and inadequate tumor resection. The latest TNM (tumor, lymph node, metastasis) classification of cSCC published by the American Joint Committee on Cancer (AJCC) in the seventh edition of its Cancer Staging Manual now incorporates several of these risk factors to improve disease staging. We review all the factors currently considered to be markers of poor prognosis in cSCC and analyze the new AJCC classification and the different treatment options for high-risk cSCC.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">El carcinoma epidermoide cutáneo (CEC) es la segunda neoplasia cutánea más frecuente y su incidencia está aumentando en las últimas décadas. La mayoría de los tumores se van a resolver con cirugía, pero alrededor de un 5% van a presentar metástasis locales y a distancia; esta proporción será mayor en algunos CEC que presenten determinados factores denominados de alto riesgo: tamaño tumoral (mayor de 2<span class="elsevierStyleHsp" style=""></span>cm), profundidad de invasión (superior a 2<span class="elsevierStyleHsp" style=""></span>mm), nivel de Clark (IV o superior), invasión perineural, invasión linfovascular, el grado de diferenciación (tumores pobremente diferenciados), tipo histológico (desmoplásico, adenoescamoso, enfermedad de Bowen invasiva o el CEC que aparece sobre un proceso inflamatorio crónico), inmunosupresión, infección por el virus del papiloma humano (VPH), localización en zonas de alto riesgo (pabellón auricular, mucosa labial), expresión de ciertos genes tumorales, o una inadecuada resección del tumor. La séptima y última clasificación TNM de la <span class="elsevierStyleItalic">American Joint Committe on Cancer</span> (AJCC) ha incluido algunos de estos factores de riesgo obteniendo de esta forma un mejor estadiaje. Realizamos una revisión de todos los factores de mal pronóstico del CEC y analizamos la nueva clasificación de la AJCC, así como las opciones terapéuticas del CEC de alto riesgo.</p>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara">Please cite this article as: Nuño-González A, Vicente-Martín FJ, Pinedo-Moraleda F y López-Estebaranz JL. Carcinoma epidermoide cutáneo de alto riesgo. Actas Dermosifiliogr.2012;103:567-578.</p>" ] ] "multimedia" => array:11 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 713 "Ancho" => 951 "Tamanyo" => 200225 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Poorly differentiated nodular squamous cell carcinoma of the skin (hematoxylin-eosin, original magnification ×10).</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 760 "Ancho" => 951 "Tamanyo" => 376382 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Cutaneous squamous cell carcinoma that has invaded the deep dermis and hypodermis; Clark level IV (hematoxylin-eosin, original magnification ×10).</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 760 "Ancho" => 951 "Tamanyo" => 436026 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Cutaneous squamous cell carcinoma around a nerve sheath. Perineural invasion is clearly visible (hematoxylin-eosin, original magnification ×100).</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 2079 "Ancho" => 1600 "Tamanyo" => 430178 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">A, Large cutaneous squamous cell carcinoma located in the left frontoparietal region. This tumor has several high-risk features, including its size, its depth, a Clark level of IV (periosteal invasion), and poor differentiation. B, Computed tomography scan of the same patient showing parotid metastases. C, Photograph of the same patient following surgical treatment of the tumor, showing ipsilateral parotid metastases and facial paralysis resulting from tumoral invasion of cranial nerve VII.</p>" ] ] 4 => array:7 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 713 "Ancho" => 951 "Tamanyo" => 342421 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Poorly differentiated cutaneous squamous cell carcinoma. Tumor cell nests with central necrosis can be seen in some areas (hematoxylin-eosin, original magnification ×40).</p>" ] ] 5 => array:7 [ "identificador" => "fig0030" "etiqueta" => "Figure 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 759 "Ancho" => 951 "Tamanyo" => 172025 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Cutaneous squamous cell carcinoma on the lower lip. This location is considered to be a high-risk feature and has been included in the most recent staging criteria published by the American Joint Committee on Cancer.</p>" ] ] 6 => array:7 [ "identificador" => "fig0035" "etiqueta" => "Figure 7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr7.jpeg" "Alto" => 988 "Ancho" => 1600 "Tamanyo" => 217338 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">A, Cutaneous squamous cell carcinoma on the cheek. B, Scar left by excision of the tumor and a macroscopically evident enlarged lymph node in the drainage region of the tumor, with associated parotid metastasis, which worsens prognosis.</p>" ] ] 7 => array:7 [ "identificador" => "fig0040" "etiqueta" => "Figure 8" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr8.jpeg" "Alto" => 760 "Ancho" => 951 "Tamanyo" => 415783 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Cutaneous squamous cell carcinoma in which several high-risk features—including moderate-to-poor histological differentiation, deep invasion (Clark level IV), and perineural invasion of a nerve sheath—can be observed microscopically (hematoxylin-eosin, original magnification ×20).</p>" ] ] 8 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">1.1 T: Tumor size</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Tx \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Primary tumor cannot be assessed \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No evidence of primary tumor \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Tis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Carcinoma in situ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor 2<span class="elsevierStyleHsp" style=""></span>cm or less in greatest dimension with fewer than 2 high-risk features<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor greater than 2<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension, or tumor of any size with 2 or more high-risk features<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor with invasion of maxilla, mandible, orbit, or temporal bone \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor with invasion of skeleton or perineural invasion of skull base \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">1.2 N: Lymph node involvement</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Nx \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Regional lymph nodes cannot be assessed \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No regional lymph node metastasis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metastasis in a single ipsilateral lymph node, 3<span class="elsevierStyleHsp" style=""></span>cm or less in greatest dimension \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metastasis in a single ipsilateral lymph node, more than 3<span class="elsevierStyleHsp" style=""></span>cm but not more than 6<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N2a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metastasis in a single ipsilateral lymph node, more than 3<span class="elsevierStyleHsp" style=""></span>cm but not more than 6<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N2b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metastasis in multiple ipsilateral lymph nodes, none more than 6<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N2c \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metastasis in bilateral or contralateral lymph nodes, none more than 6<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metastasis in a lymph node, more than 6<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">1.3 M: Distant metastasis</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No distant metastasis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Distant metastasis \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182289.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara">High-risk features for primary tumor staging: depth/invasion, > 2<span class="elsevierStyleHsp" style=""></span>mm; thickness, Clark level ≥ IV; perineural invasion; anatomic location (primary site ear, primary site lip); differentiation (poorly differentiated or undifferentiated).</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Current TNM Classification According to the Seventh Edition of the Cancer Staging Manual of the American Joint Committee on Cancer (AJCC).</p>" ] ] 9 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage 0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stage IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T1-T3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T any \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N any \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T any \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N any \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M1 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182290.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Cutaneous Squamous Cell Carcinoma Staging.</p>" ] ] 10 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: cSCC, cutaneous squamous cell carcinoma; HPV, human papillomavirus</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Size (greater than 2<span class="elsevierStyleHsp" style=""></span>cm in greatest dimension) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Thickness (greater than 2<span class="elsevierStyleHsp" style=""></span>mm) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Perineural invasion \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Lymphatic or vascular invasion \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Histologic subtype (desmoplastic or adenosquamous carcinoma, invasive Bowen disease, or a cSCC arising in an area of chronic inflammation) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Poor differentiation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Immunosuppression \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- HPV infection \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- High-risk anatomic location (ear, lip) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Drainage areas \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Inadequate tumor resection or tumor with tendency towards recurrence \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">- Expression of tumor genes \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182288.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Summary of High-Risk Features of cSCC.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:50 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. García-Zuazaga" 1 => "S.M. Olbricht" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Adv Dermatol" "fecha" => "2008" "volumen" => "24" "paginaInicial" => "33" "paginaFinal" => "57" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19256304" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The need for a better prognostic staging system in patients with metastatic cutaneous squamous cell carcinoma of the head and neck" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C.E. Palme" 1 => "S.G. MacKay" 2 => "I. Kalnins" 3 => "G.J. Morgan" 4 => "M.J. Veness" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Curr Opin Otolaryngol Head Neck Surg" "fecha" => "2007" "volumen" => "15" "paginaInicial" => "1036" "itemHostRev" => array:3 [ "pii" => "S0010782408002849" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The epidemiology of skin cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T.L. Diepgen" 1 => "V. Mahler" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2002" "volumen" => "146" "paginaInicial" => "1" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11966724" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mortality risk from squamous cell skin cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.L. Clayman" 1 => "J.J. Lee" 2 => "F.C. Holsinger" 3 => "X. Zhou" 4 => "M. Duvic" 5 => "A.K. El-Naggar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.02.155" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2005" "volumen" => "23" "paginaInicial" => "759" "paginaFinal" => "765" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15681519" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evolución de la incidencia del cáncer de piel en el período 1978-2002" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Aceituno-Madera" 1 => "A. Buendia-Eisman" 2 => "S. Arias-Santiago" 3 => "S. Serrano Ortega" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2010" "volumen" => "101" "paginaInicial" => "39" "paginaFinal" => "46" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20109391" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673606685425" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Focus issue on squamous cell carcinoma: practical concerns regarding the 7th edition AJCC staging guidelines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D. Buethe" 1 => "C. Warner" 2 => "J. Miedler" 3 => "C.J. Cockerell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2011/156391" "Revista" => array:5 [ "tituloSerie" => "J Skin Cancer" "fecha" => "2011" "volumen" => "2011" "paginaInicial" => "156391" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21151529" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interventions for non-metastatic squamous cell carcinoma of the skin" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Lansbury" 1 => "J. Leonardi-Bee" 2 => "W. Perkins" 3 => "T. Goodacre" 4 => "F.J. Bath-Hetxall" 5 => "J.A. Tweed" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "titulo" => "Cochrane Database of Systematic Reviews" "fecha" => "2009" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Oddone" 1 => "G.J. Morgan" 2 => "C.E. Palme" 3 => "L. Perera" 4 => "J. Shannon" 5 => "E. Wong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.24208" "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "2009" "volumen" => "115" "paginaInicial" => "1883" "paginaFinal" => "1891" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19224549" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.J. Veness" 1 => "C.E. Palme" 2 => "G.J. Morgan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.21898" "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "2006" "volumen" => "106" "paginaInicial" => "2389" "paginaFinal" => "2396" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16649220" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Farasat" 1 => "S.S. Yu" 2 => "V.A. Neel" 3 => "K.S. Nehal" 4 => "T. Lardaro" 5 => "M.C. Mihm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2010.08.033" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2011" "volumen" => "64" "paginaInicial" => "1051" "paginaFinal" => "1059" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21255868" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.D. Brantsch" 1 => "C. Meisner" 2 => "B. Schönfisch" 3 => "B. Trilling" 4 => "J. Wehner-Caroli" 5 => "M. Röcken" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(08)70178-5" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "713" "paginaFinal" => "720" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18617440" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metastatic cutaneous squamous cell carcinoma: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.S. Weinberg" 1 => "C.A. Ogle" 2 => "E.K. Shim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1524-4725.2007.33190.x" "Revista" => array:6 [ "tituloSerie" => "Dermatol Surg" "fecha" => "2007" "volumen" => "33" "paginaInicial" => "885" "paginaFinal" => "899" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17661931" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Invasive squamous cell carcinoma of the skin: defining a high-risk group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.T. Mullen" 1 => "L. Feng" 2 => "Y. Xing" 3 => "P.F. Mansfield" 4 => "J.E. Gershenwald" 5 => "J.E. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1245/ASO.2006.07.022" "Revista" => array:6 [ "tituloSerie" => "Ann Surg Oncol" "fecha" => "2006" "volumen" => "13" "paginaInicial" => "902" "paginaFinal" => "909" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16788750" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "British Association of Dermatologists Clinical Standards Unit. Revised U.K. guidelines for the management of cutaneous melanoma 2010" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.R. Marsden" 1 => "J.A. Newton-Bishop" 2 => "L. Burrows" 3 => "M. Cook" 4 => "P.G. Corrie" 5 => "N.H. Cox" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2010.09883.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2010" "volumen" => "163" "paginaInicial" => "238" "paginaFinal" => "256" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20608932" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Defining patients with high-risk cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.J. Veness" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1440-0960.2006.00218.x" "Revista" => array:6 [ "tituloSerie" => "Australas J Dermatol" "fecha" => "2006" "volumen" => "47" "paginaInicial" => "28" "paginaFinal" => "33" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16405479" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carcinoma of the skin with perineural invasion" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. García-Serra" 1 => "R.W. Hinerman" 2 => "W.M. Mendenhall" 3 => "R.J. Amdur" 4 => "C.G. Morris" 5 => "L.S. Williams" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hed.10334" "Revista" => array:6 [ "tituloSerie" => "Head Neck" "fecha" => "2003" "volumen" => "25" "paginaInicial" => "1027" "paginaFinal" => "1033" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14648861" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.J. Veness" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1440-1673.2005.01496.x" "Revista" => array:7 [ "tituloSerie" => "Australas Radiol" "fecha" => "2005" "volumen" => "49" "paginaInicial" => "365" "paginaFinal" => "376" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16174174" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442206705373" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Jambusaria-Pahlajani" 1 => "C.J. Miller" 2 => "H. Quon" 3 => "N. Smith" 4 => "R.Q. Klein" 5 => "C.D. Schmults" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatol Surg" "fecha" => "2009" "volumen" => "35" "paginaInicial" => "574" "paginaFinal" => "585" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19415791" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.S. Ross" 1 => "F.M. Whalen" 2 => "R. Elenitsas" 3 => "X. Xu" 4 => "A.B. Troxel" 5 => "C.D. Schmults" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1524-4725.2009.01354.x" "Revista" => array:6 [ "tituloSerie" => "Dermatol Surg" "fecha" => "2009" "volumen" => "35" "paginaInicial" => "1859" "paginaFinal" => "1866" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19889009" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.A. Moore" 1 => "R.S. Weber" 2 => "V. Prieto" 3 => "A. El-Naggar" 4 => "F.C. Holsinger" 5 => "X. Zhou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.mlg.0000173202.56739.9f" "Revista" => array:6 [ "tituloSerie" => "Laryngoscope" "fecha" => "2005" "volumen" => "115" "paginaInicial" => "1561" "paginaFinal" => "1567" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16148695" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.S. Cassarino" 1 => "D.P. Derienzo" 2 => "R.J. Barr" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Cutan Pathol" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "191206" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part two" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.S. Cassarino" 1 => "D.P. Derienzo" 2 => "R.J. Barr" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Cutan Pathol" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "26179" "itemHostRev" => array:3 [ "pii" => "S0010782407005008" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carcinoma epidermoide sobre lupus vulgar" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Sabat" 1 => "M. Ribera" 2 => "J.M. Casanova" 3 => "I. Bielsa" 4 => "M.J. Fuente" 5 => "C. Ferrándiz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2003" "volumen" => "94" "paginaInicial" => "616" "paginaFinal" => "619" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histopathological variants of cutaneous squamous cell carcinoma: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "V.R. Yanofsky" 1 => "S.E. Mercer" 2 => "R.G. Phelps" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2011/210813" "Revista" => array:5 [ "tituloSerie" => "J Skin Cancer" "fecha" => "2011" "volumen" => "2011" "paginaInicial" => "210813" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21234325" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Ramachandran" 1 => "R. Rajaratnam" 2 => "A.G. Smith" 3 => "J.T. Lear" 4 => "R.C. Strange" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2009.03.015" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2009" "volumen" => "61" "paginaInicial" => "247" "paginaFinal" => "251" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19481292" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.N. de Koning" 1 => "S.J. Weissenborn" 2 => "D. Abeni" 3 => "J.N. Bouwes Bavinck" 4 => "S. Euvrard" 5 => "A.C. Green" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1099/vir.0.010017-0" "Revista" => array:6 [ "tituloSerie" => "J Gen Virol" "fecha" => "2009" "volumen" => "90" "paginaInicial" => "1611" "paginaFinal" => "1621" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19321753" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.N. Bouwes Bavinck" 1 => "R.E. Neale" 2 => "D. Abeni" 3 => "S. Euvrard" 4 => "A.C. Green" 5 => "C.A. Harwood" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/0008-5472.CAN-10-0352" "Revista" => array:6 [ "tituloSerie" => "Cancer Res" "fecha" => "2010" "volumen" => "70" "paginaInicial" => "9777" "paginaFinal" => "9786" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21098702" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of high-risk cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Jennings" 1 => "D. Schmults" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Aesthetic Dermatol" "fecha" => "2010" "volumen" => "3" "paginaInicial" => "39" "paginaFinal" => "48" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma: a case-control study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A.S. Patel" 1 => "M.R. Karagas" 2 => "M. Pawlita" 3 => "T. Waterboer" 4 => "H.H. Nelson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ijc.23377" "Revista" => array:6 [ "tituloSerie" => "Int J Cancer" "fecha" => "2008" "volumen" => "122" "paginaInicial" => "2377" "paginaFinal" => "2379" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18224692" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carcinoma epidermoide sobre queratosis seborreica" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Carnero" 1 => "R. Soloeta" 2 => "N. Arbide" 3 => "R. González-Pérez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2009" "volumen" => "100" "paginaInicial" => "621" "paginaFinal" => "622" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19715652" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The sero-epidemiology of human papillomavirus among caucasian transplant recipients in the UK" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Casabonne" 1 => "T. Waterboer" 2 => "K.M. Michael" 3 => "M. Pawlita" 4 => "A. Lally" 5 => "L. Mitchell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1750-9378-4-13" "Revista" => array:5 [ "tituloSerie" => "Infect Agent Cancer" "fecha" => "2009" "volumen" => "4" "paginaInicial" => "13" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19751499" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Parotid and cervical nodal status predict prognosis for patients with head and neck metastatic cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Ch’ng" 1 => "A. Maitra" 2 => "R.S. Allison" 3 => "J.M. Chaplin" 4 => "R.T. Gregor" 5 => "R. Lea" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jso.21092" "Revista" => array:6 [ "tituloSerie" => "J Surg Oncol" "fecha" => "2008" "volumen" => "98" "paginaInicial" => "101" "paginaFinal" => "105" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18523982" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metastatic cutaneous squamous cell carcinoma of the scalp" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.R. Howle" 1 => "G.J. Morgan" 2 => "I. Kalnins" 3 => "C.E. Palme" 4 => "M.J. Veness" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1445-2197.2008.04533.x" "Revista" => array:6 [ "tituloSerie" => "ANZ J Surg" "fecha" => "2008" "volumen" => "78" "paginaInicial" => "449" "paginaFinal" => "453" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18522564" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carcinoma epidermoide desarrollado sobre quiste de inclusión epidérmica cutánea. Presentación de un nuevo caso y revisión de la literatura" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "I. Antón-Badiola" 1 => "P. San Miguel-Fraile" 2 => "A. Peteiro-Cancelo" 3 => "J.A. Ortiz-Rey" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2010" "volumen" => "101" "paginaInicial" => "349" "paginaFinal" => "353" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20487691" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metastatic cutaneous squamous cell carcinoma to the parotid and cervical lymph nodes: treatment and outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Bumpous" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MOO.0b013e32832924e0" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Otolaryngol Head Neck Surg" "fecha" => "2009" "volumen" => "17" "paginaInicial" => "122" "paginaFinal" => "125" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19346945" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C.J. O’Brien" 1 => "E.B. McNeil" 2 => "J.D. McMahon" 3 => "I. Pathak" 4 => "C.S. Lauer" 5 => "M.A. Jackson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hed.10063" "Revista" => array:6 [ "tituloSerie" => "Head Neck" "fecha" => "2002" "volumen" => "24" "paginaInicial" => "417" "paginaFinal" => "422" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12001070" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Ch’ng" 1 => "I. Low" 2 => "D. Ng" 3 => "H. Brasch" 4 => "M. Sullivan" 5 => "P. Davis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.humpath.2007.07.004" "Revista" => array:6 [ "tituloSerie" => "Hum Pathol" "fecha" => "2008" "volumen" => "39" "paginaInicial" => "344" "paginaFinal" => "349" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18045646" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Jambusaria-Pahlajani" 1 => "S.D. Hess" 2 => "K.A. Katz" 3 => "D. Berg" 4 => "C.D. Schmults" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archdermatol.2010.323" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2010" "volumen" => "146" "paginaInicial" => "1225" "paginaFinal" => "1231" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21079057" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiotherapy for locally advanced basal cell carcinoma and squamous cell carcinomas of the skin" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "W. Kwan" 1 => "D. Wilson" 2 => "V. Moravan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijrobp.2004.03.006" "Revista" => array:6 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "2004" "volumen" => "60" "paginaInicial" => "406" "paginaFinal" => "411" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15380573" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estudio del ganglio centinela en el cáncer cutáneo no melanoma: situación actual" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Toll-Abelló" 1 => "R.M. Pujol-Vallverdú" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Piel" "fecha" => "2006" "volumen" => "21" "paginaInicial" => "127" "paginaFinal" => "134" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Usefulness of real-time tissue elastography for detecting lymph-node metastases in squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Aoyagi" 1 => "K. Izumi" 2 => "H. Hata" 3 => "H. Kawasaki" 4 => "H. Shimizu" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2009" "volumen" => "34" "paginaInicial" => "744" "paginaFinal" => "747" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Central nodal necrosis and extracapsular neoplastic spread in cervical lymph nodes: MR imaging versus CT" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D.M. Yousem" 1 => "P.M. Som" 2 => "D.B. Hackney" 3 => "Schwaibold F." 4 => "R.A. Hendrix" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiology.182.3.1535890" "Revista" => array:7 [ "tituloSerie" => "Radiology" "fecha" => "1992" "volumen" => "182" "paginaInicial" => "753" "paginaFinal" => "759" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1535890" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442207701783" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MR imaging of perineural tumor spread" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "L.E. Ginsberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Magn Reson Imaging Clin N Am" "fecha" => "2002" "volumen" => "10" "paginaInicial" => "511" "paginaFinal" => "525" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12530232" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Positron emission tomography and assessment of cancer therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.E. Juweid" 1 => "B.D. Cheson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra050276" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2006" "volumen" => "354" "paginaInicial" => "496" "paginaFinal" => "507" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16452561" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.A. Harwood" 1 => "M. Leedham-Green" 2 => "I.M. Leigh" 3 => "C.M. Proby" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.141.4.456" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2005" "volumen" => "141" "paginaInicial" => "456" "paginaFinal" => "464" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15837863" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nonsurgical innovations in the treatment of nonmelanoma skin cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Amini" 1 => "M.H. Viera" 2 => "W. Valins" 3 => "B. Berman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Aesthet Dermatol" "fecha" => "2010" "volumen" => "3" "paginaInicial" => "20" "paginaFinal" => "34" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21103312" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biopsia selectiva de ganglio centinela en tumores cutáneos no melanoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.P. Cózar" 1 => "J. Ferrer-Rebolleda" 2 => "M.C. Redal" 3 => "A. Moreno" 4 => "L. Tortajada" 5 => "I. Casáns" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Esp Med Nucl" "fecha" => "2006" "volumen" => "25" "paginaInicial" => "10" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16540005" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.A. Bonner" 1 => "P.M. Harari" 2 => "J. Giralt" 3 => "R.B. Cohen" 4 => "C.U. Jones" 5 => "R.K. Sur" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(09)70311-0" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2010" "volumen" => "11" "paginaInicial" => "21" "paginaFinal" => "28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19897418" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective multicenter phase IB/II trial (SAKK 75/06)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Ruhstaller" 1 => "M. Pless" 2 => "D. Dietrich" 3 => "H. Kranzbuehler" 4 => "R. von Moos" 5 => "P. Moosmann" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "26" "paginaFinal" => "31" ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of unresectable and metastatic cutaneous squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L.D. Cranmer" 1 => "C. Engelhardt" 2 => "S.S. Morgan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1634/theoncologist.2009-0210" "Revista" => array:7 [ "tituloSerie" => "Oncologist" "fecha" => "2010" "volumen" => "15" "paginaInicial" => "1320" "paginaFinal" => "1328" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21147868" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0010782409003801" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010300000007/v1_201304241318/S1578219012002156/v1_201304241318/en/main.assets" "Apartado" => array:4 [ "identificador" => "6177" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Reviews" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010300000007/v1_201304241318/S1578219012002156/v1_201304241318/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002156?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 32 | 9 | 41 |
| 2024 Octubre | 342 | 42 | 384 |
| 2024 Septiembre | 522 | 26 | 548 |
| 2024 Agosto | 573 | 64 | 637 |
| 2024 Julio | 655 | 39 | 694 |
| 2024 Junio | 556 | 39 | 595 |
| 2024 Mayo | 547 | 63 | 610 |
| 2024 Abril | 428 | 41 | 469 |
| 2024 Marzo | 450 | 42 | 492 |
| 2024 Febrero | 554 | 34 | 588 |
| 2024 Enero | 467 | 43 | 510 |
| 2023 Diciembre | 543 | 30 | 573 |
| 2023 Noviembre | 1090 | 50 | 1140 |
| 2023 Octubre | 666 | 32 | 698 |
| 2023 Septiembre | 543 | 31 | 574 |
| 2023 Agosto | 273 | 26 | 299 |
| 2023 Julio | 201 | 53 | 254 |
| 2023 Junio | 143 | 40 | 183 |
| 2023 Mayo | 179 | 29 | 208 |
| 2023 Abril | 233 | 36 | 269 |
| 2023 Marzo | 214 | 31 | 245 |
| 2023 Febrero | 183 | 42 | 225 |
| 2023 Enero | 165 | 34 | 199 |
| 2022 Diciembre | 187 | 38 | 225 |
| 2022 Noviembre | 131 | 45 | 176 |
| 2022 Octubre | 140 | 33 | 173 |
| 2022 Septiembre | 138 | 32 | 170 |
| 2022 Agosto | 102 | 34 | 136 |
| 2022 Julio | 87 | 37 | 124 |
| 2022 Junio | 85 | 29 | 114 |
| 2022 Mayo | 144 | 52 | 196 |
| 2022 Abril | 161 | 55 | 216 |
| 2022 Marzo | 154 | 59 | 213 |
| 2022 Febrero | 158 | 36 | 194 |
| 2022 Enero | 215 | 49 | 264 |
| 2021 Diciembre | 150 | 55 | 205 |
| 2021 Noviembre | 180 | 65 | 245 |
| 2021 Octubre | 179 | 58 | 237 |
| 2021 Septiembre | 135 | 54 | 189 |
| 2021 Agosto | 106 | 47 | 153 |
| 2021 Julio | 114 | 42 | 156 |
| 2021 Junio | 193 | 48 | 241 |
| 2021 Mayo | 130 | 46 | 176 |
| 2021 Abril | 356 | 67 | 423 |
| 2021 Marzo | 205 | 43 | 248 |
| 2021 Febrero | 149 | 41 | 190 |
| 2021 Enero | 106 | 26 | 132 |
| 2020 Diciembre | 146 | 56 | 202 |
| 2020 Noviembre | 82 | 22 | 104 |
| 2020 Octubre | 89 | 20 | 109 |
| 2020 Septiembre | 128 | 21 | 149 |
| 2020 Agosto | 116 | 36 | 152 |
| 2020 Julio | 325 | 16 | 341 |
| 2020 Junio | 270 | 33 | 303 |
| 2020 Mayo | 135 | 23 | 158 |
| 2020 Abril | 72 | 24 | 96 |
| 2020 Marzo | 64 | 40 | 104 |
| 2020 Febrero | 5 | 4 | 9 |
| 2020 Enero | 4 | 2 | 6 |
| 2019 Diciembre | 4 | 7 | 11 |
| 2019 Noviembre | 4 | 4 | 8 |
| 2019 Octubre | 0 | 2 | 2 |
| 2019 Septiembre | 0 | 7 | 7 |
| 2019 Agosto | 6 | 2 | 8 |
| 2019 Julio | 4 | 2 | 6 |
| 2019 Junio | 4 | 6 | 10 |
| 2019 Mayo | 4 | 17 | 21 |
| 2019 Abril | 3 | 4 | 7 |
| 2019 Marzo | 2 | 8 | 10 |
| 2019 Enero | 3 | 0 | 3 |
| 2018 Diciembre | 3 | 0 | 3 |
| 2018 Noviembre | 1 | 0 | 1 |
| 2018 Octubre | 2 | 0 | 2 |
| 2018 Septiembre | 7 | 0 | 7 |
| 2018 Agosto | 0 | 1 | 1 |
| 2018 Julio | 0 | 5 | 5 |
| 2018 Mayo | 0 | 9 | 9 |
| 2018 Abril | 0 | 1 | 1 |
| 2018 Marzo | 6 | 4 | 10 |
| 2018 Febrero | 243 | 11 | 254 |
| 2018 Enero | 256 | 10 | 266 |
| 2017 Diciembre | 239 | 18 | 257 |
| 2017 Noviembre | 200 | 15 | 215 |
| 2017 Octubre | 203 | 8 | 211 |
| 2017 Septiembre | 170 | 21 | 191 |
| 2017 Agosto | 196 | 18 | 214 |
| 2017 Julio | 132 | 23 | 155 |
| 2017 Junio | 197 | 29 | 226 |
| 2017 Mayo | 136 | 23 | 159 |
| 2017 Abril | 111 | 15 | 126 |
| 2017 Marzo | 129 | 33 | 162 |
| 2017 Febrero | 95 | 35 | 130 |
| 2017 Enero | 215 | 93 | 308 |
| 2016 Diciembre | 238 | 92 | 330 |
| 2016 Noviembre | 286 | 84 | 370 |
| 2016 Octubre | 359 | 31 | 390 |
| 2016 Septiembre | 424 | 42 | 466 |
| 2016 Agosto | 395 | 26 | 421 |
| 2016 Julio | 215 | 20 | 235 |
| 2016 Junio | 20 | 21 | 41 |
| 2016 Mayo | 11 | 39 | 50 |
| 2016 Abril | 6 | 8 | 14 |
| 2016 Marzo | 10 | 15 | 25 |
| 2016 Febrero | 16 | 7 | 23 |
| 2016 Enero | 12 | 3 | 15 |
| 2015 Diciembre | 17 | 7 | 24 |
| 2015 Noviembre | 46 | 8 | 54 |
| 2015 Octubre | 78 | 5 | 83 |
| 2015 Septiembre | 78 | 5 | 83 |
| 2015 Agosto | 41 | 6 | 47 |
| 2015 Julio | 222 | 19 | 241 |
| 2015 Junio | 189 | 23 | 212 |
| 2015 Mayo | 262 | 31 | 293 |
| 2015 Abril | 220 | 23 | 243 |
| 2015 Marzo | 305 | 28 | 333 |
| 2015 Febrero | 227 | 33 | 260 |
| 2015 Enero | 146 | 17 | 163 |
| 2014 Diciembre | 158 | 15 | 173 |
| 2014 Noviembre | 160 | 14 | 174 |
| 2014 Octubre | 177 | 30 | 207 |
| 2014 Septiembre | 163 | 23 | 186 |
| 2014 Agosto | 125 | 11 | 136 |
| 2014 Julio | 119 | 13 | 132 |
| 2014 Junio | 133 | 16 | 149 |
| 2014 Mayo | 133 | 11 | 144 |
| 2014 Abril | 122 | 13 | 135 |
| 2014 Marzo | 123 | 33 | 156 |
| 2014 Febrero | 123 | 34 | 157 |
| 2014 Enero | 116 | 25 | 141 |
| 2013 Diciembre | 98 | 19 | 117 |
| 2013 Noviembre | 110 | 28 | 138 |
| 2013 Octubre | 83 | 18 | 101 |
| 2013 Septiembre | 59 | 39 | 98 |
| 2013 Agosto | 36 | 65 | 101 |
| 2013 Julio | 28 | 57 | 85 |
| 2013 Junio | 22 | 63 | 85 |
| 2013 Mayo | 22 | 53 | 75 |
| 2013 Abril | 18 | 40 | 58 |
| 2013 Marzo | 31 | 29 | 60 |
| 2013 Febrero | 47 | 8 | 55 |
| 2013 Enero | 114 | 28 | 142 |
| 2012 Diciembre | 71 | 21 | 92 |
| 2012 Noviembre | 2 | 9 | 11 |
| 2012 Octubre | 4 | 11 | 15 |
| 2012 Septiembre | 2 | 14 | 16 |
Mostrar todo
